We are international
Donate
• videos TEXT SIZE   

The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2004 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful.

ASH 2004 Presentations and Posters

THERAPIES FOR RELAPSING PATIENTS
ASH 2004: Antonio Palumbo, MD
THAL + DEX IS EFFECTIVE SALVAGE REGIMEN FOR PTS RELAPSING AFTER AUTOLOGOUS TRANSPLANT

ASH 2004: Paul G. Richardson, MD
Bortezomib vs High-Dose Dexamethasone in Relapsed Multiple Myeloma: Results of a Large Randomized Phase 3 Study

NEW AGENTS, SUPPORTIVE CARE, PROGNOSTIC FACTORS, AND MOLECULAR BIOLOGY
ASH 2004: Prof. Brian G.M. Durie, MD
Osteonecrosis of the Jaw In Myeloma:Time Dependent Correlation with AREDIA and ZOMETA Use

ASH 2004: Prof. Heinz Ludwig
Poorer Survival in Multiple Myeloma Correlates with Patients’ age and is Linked to a Higher Stage at Presentation but Prognostic Parameters Reflecting the Biology of the Myeloma Clone are not Associated with Age.

ASH 2004: Asst. Prof. Rafael Fonseca, MD
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16;q32) and -17p13 (p53) deletions in myeloma patients treated with high dose therapy.

ASH 2004: Mohamad Hussein, MD
A Phase I, Multi-Dose Study of SGN-40 (anti-huCD40 mAb) in Patients with MM

ASH 2004: Asst. Prof. William F. Matsui, MD and Carol Ann Huff, MD
Antibody-Based Therapy Targeting Myeloma Stem Cells

Meral Beksac, MD
[4869] IL-101082-A and TNF-Alpha 238/308A Genotypes Are Associated with Earlier (Younger than 55) Onset of Multiple Myeloma.

ASH 2004: Prof. John DiPersio, MD, PhD
A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor HematopoieticStem Cells in Patients with Advanced Hematological Malignancies.